Pharmaceutical composition containing antifungal agent as active ingredient

LAP824AUndetermined Publication Date: 2026-02-27SATO PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP824
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-08-13
Filing Date
2020-08-07
Publication Date
2026-02-27

AI Technical Summary

Technical Problem

Current topical pharmaceutical compositions containing antifungal drugs like luliconazole for treating onychomycosis face challenges with high concentration stability and precipitation issues, making it difficult to maintain therapeutic effectiveness over time.

Method used

A pharmaceutical composition comprising luliconazole or its pharmaceutically acceptable salt, polyethylene glycol with an average molecular weight of 380 to 420, ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone, which stabilizes luliconazole at high concentrations and prevents precipitation, allowing for improved solubility and prolonged storage stability.

Benefits of technology

The composition effectively dissolves luliconazole at high concentrations, preventing precipitation and ensuring stability over time, enhancing therapeutic efficacy and storage duration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a technique that allows a pharmaceutical composition, preferablyfor extemal use, containing luliconazole or the like to contain luliconazole or the like at a high concentration, and suppresses the precipitation thereof over time. The present invention uses a polyethylene glycol having an average molecular weight of 380 to 420 represented by a formula HOCHz(CHzOCHz).CHzOH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone in combination with the luliconazole or the like.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition containing an antifungal drug as an active ingredient

[0001] The present invention relates to a pharmaceutical composition containing an antifungal agent as an active ingredient, for the purpose of treating or preventing onychomycosis.

[0002] Onychomycosis is a nail disease caused by dermatophytes. It is a stubborn disease accompanied by symptoms such as opacity, thickening, destruction, and deformation of the nail plate. It infects humans in baths and does not heal naturally. It is estimated that approximately half of onychomycosis patients do not receive treatment. Even if treatment is received, the nail plate is dense and hard, and toenails in particular are significantly thicker than fingernails, making it difficult to deliver pharmaceutical compositions to the nail bed. Therefore, complete recovery may take more than six months or even a year.

[0003] Currently, oral medications have been developed for the treatment of onychomycosis, but they have side effects and often recur even after being cured. Therefore, topical pharmaceutical compositions containing antifungal drugs as active ingredients are mainly used.

[0004] Pharmaceutical compositions for external use containing an antifungal drug for the treatment or prevention of onychomycosis, such as luliconazole or a pharmaceutically acceptable salt thereof (hereinafter also referred to as luliconazole, etc.), are known (Patent Document 1), and preparations with concentrations of 1% and 0.5 to 5% have been put to practical use.

[0005] Regarding the components of pharmaceutical compositions for external use in which antifungal drugs are dissolved for the purpose of treating or preventing onychomycosis, research has been conducted on film-forming agents, absorption enhancers, solubilizing agents, solvents, etc., and many patents have been published (Patent Documents 2 to 13).

[0006] Examples of the film-forming agent include alkyd resins, butyl acrylate-methacrylic acid copolymers (Patent Document 14), or mixtures of copolymer AMP and ethanol, such as a mixture of acrylic (alkyl acrylate / diacetone acrylamide) copolymer AMP and ethanol.

[0007] Examples of the absorption enhancers include urea, salicylic acid, diisopropyl myristate, N-methyl-2-pyrrolidone, diisopropyl adipate (Patent Document 15), dimethylformamide, dimethyl sulfoxide (Patent Document 3), and propylene glycol.

[0008] Examples of the solubilizing agent include acetone, propylene carbonate, benzyl alcohol, triacetin, lactic acid, and crotamiton (Patent Document 15).

[0009] Examples of the solvent include ethyl acetate, butyl acetate, ethanol, isopropanol, diisopropyl sebacate (Patent Documents 14 and 16), diethylene glycol dibutyl ether (Patent Document 17), xylene, and dimethylacetamide.

[0010] Patent No. 3278738 Patent No. 5160409 Patent No. 5184341 Patent No. 5184342 Patent No. 5688405 Patent No. 5635075 Patent No. 5529539 Patent No. 5345937 Patent No. 5453093 Patent No. 5688406 Patent No. 5832451 Patent No. 5938497 Patent No. 5654497 Patent No. 3803393 International Publication No. 96 / 11710 Japanese Patent Laid-Open No. 6-211651 Special Publication No. 2004-529923

[0011] As described above, topical pharmaceutical compositions containing luliconazole or the like dissolved therein for the purpose of treating or preventing onychomycosis have been put to practical use up to a concentration of 5%, but higher concentrations and stabilization are desired for further improvement in therapeutic effect. However, it is known that compositions containing more than 5% of luliconazole or the like are unstable, and luliconazole or the like precipitates from the solution during storage or after application to the nail.

[0012] The present invention provides a technology for containing luliconazole etc. at a high concentration and suppressing its precipitation over time in a pharmaceutical composition, preferably for external use, containing luliconazole etc.

[0013] In view of this situation, the present inventors have investigated the combination of solvents that can stably dissolve luliconazole and the like at high concentrations over time, and have found that the compound represented by the formula HOCH2(CH2OCH2) nThe inventors have found that polyethylene glycol having an average molecular weight of 380 to 420, represented by CHOH (where n is an integer), can stably dissolve luliconazole and the like at a high concentration, and have also found that the combined use of ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone can improve the solubility of luliconazole and the like and inhibit its precipitation over time, thereby completing the present invention.

[0014] That is, the present invention is as follows: [1] A pharmaceutical composition containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, the pharmaceutical composition comprising 5 to 12% by mass of luliconazole or a pharmaceutically acceptable salt thereof relative to the total mass of the pharmaceutical composition, and a compound represented by the formula HOCH2(CHOCH2). n [2] A pharmaceutical composition comprising polyethylene glycol having an average molecular weight of 380 to 420, represented by the formula HOCH2(CHOCH2), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone. [3] The pharmaceutical composition according to [1] above, comprising 7 to 10% by mass of luliconazole or a pharmaceutically acceptable salt thereof, based on the total mass of the pharmaceutical composition. [4] A pharmaceutical composition comprising 5 to 40% by mass of a compound of the formula HOCH2(CHOCH2), based on the total mass of the pharmaceutical composition. nThe pharmaceutical composition according to [1] or [2] above, comprising polyethylene glycol represented by CHOH (wherein n is an integer) and having an average molecular weight of 380 to 420. [4] The pharmaceutical composition according to any one of [1] to [3] above, comprising 20 to 70% by mass of ethanol relative to the total mass of the pharmaceutical composition. [5] The pharmaceutical composition according to [4] above, comprising 30% by mass or more and less than 50% by mass of ethanol relative to the total mass of the pharmaceutical composition. [6] The pharmaceutical composition according to any one of [1] to [5] above, comprising 0.01 to 10% by mass of benzyl alcohol relative to the total mass of the pharmaceutical composition. [7] The pharmaceutical composition according to any one of [1] to [6] above, comprising 1 to 10% by mass of lactic acid relative to the total mass of the pharmaceutical composition. [8] The pharmaceutical composition according to any one of [1] to [7] above, comprising 1 to 15% by mass of propylene carbonate relative to the total mass of the pharmaceutical composition. [9] The pharmaceutical composition according to any one of [1] to [8] above, comprising 1 to 25% by mass of acetone, based on the total mass of the pharmaceutical composition.

[10] The pharmaceutical composition according to any one of [1] to [9] above, further comprising isopropyl myristate.

[11] The pharmaceutical composition according to

[10] above, comprising 1 to 10% by mass of isopropyl myristate, based on the total mass of the pharmaceutical composition.

[12] The pharmaceutical composition according to any one of [1] to

[11] above, further comprising a film-forming agent.

[13] The pharmaceutical composition according to

[12] above, wherein the film-forming agent comprises a mixture of acrylic resin alkanolamine and ethanol, or a mixture of (alkyl acrylate / diacetoneacrylamide) copolymer AMP and ethanol.

[14] The pharmaceutical composition according to

[12] or

[13] above, comprising 0.01 to 4% by mass of a film-forming agent, based on the total mass of the pharmaceutical composition.

[15] The pharmaceutical composition according to any one of [1] to

[14] above, further comprising N-methyl-2-pyrrolidone.

[16] The pharmaceutical composition according to any one of [1] to

[14] above, which does not contain N-methyl-2-pyrrolidone.

[17] The pharmaceutical composition according to any one of [1] to

[16] above, for the treatment or prevention of onychomycosis.

[18] The pharmaceutical composition according to

[17] above, wherein the onychomycosis is distal subungual onychomycosis.

[19] The pharmaceutical composition according to

[17] or

[18] above, wherein the onychomycosis is an infection of the toenails.

[20] The pharmaceutical composition according to

[17] or

[18] , wherein the onychomycosis is an infection of the fingernails.

[21] The pharmaceutical composition according to any one of [1] to

[20] , which is an external medication.

[22] The pharmaceutical composition according to

[21] , which is applied to the affected area once daily.

[23] A method for preparing the pharmaceutical composition according to any one of [1] to

[22] , comprising: adding luliconazole or a pharmaceutically acceptable salt thereof to a compound of the formula HOCH2(CHOCH2). n A method comprising mixing polyethylene glycol having an average molecular weight of 380 to 420, represented by the formula CHOH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone.

[0015] According to the present invention, it is possible to provide a pharmaceutical composition, preferably for external use, that dissolves luliconazole etc. at a high concentration, is stable over time, does not precipitate luliconazole etc., and can be stored for a long period of time. The pharmaceutical composition of the present invention may contain luliconazole etc. in an amount of preferably 5% by mass or more, more preferably 10% by mass.

[0016] The present invention provides a pharmaceutical composition containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, the pharmaceutical composition comprising 5 to 12% by mass of luliconazole or a pharmaceutically acceptable salt thereof relative to the total mass of the pharmaceutical composition, and a compound represented by the formula HOCH2(CHOCH2) n The present invention relates to a pharmaceutical composition comprising polyethylene glycol having an average molecular weight of 380 to 420 and represented by CHOH (wherein n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone.

[0017] The pharmaceutical composition of the present invention contains luliconazole etc. as an active ingredient.

[0018] Luliconazole is a known compound represented by the chemical name (R)-(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile, and its preparation method and antifungal properties are already known. Furthermore, the "pharmaceutically acceptable salt" is not particularly limited as long as it is physiologically acceptable, and suitable examples include mineral acid salts such as hydrochloride, nitrate, sulfate, and phosphate; organic acid salts such as citrate, oxalate, lactate, and acetate; and sulfate-containing salts such as mesylate and tosylate. From the standpoints of safety and solubility, hydrochloride is more preferred.

[0019] In the pharmaceutical composition of the present invention, the content of luliconazole etc. is 5 to 12% by mass, preferably more than 5% by mass, more preferably 6 to 11%, 7 to 10%, 8 to 10%, or 9 to 10% by mass, and particularly preferably 10% by mass, relative to the total mass of the pharmaceutical composition. The higher the content of luliconazole etc., the higher the therapeutic effect can be expected. When the content of luliconazole etc. is 12% by mass or less, its precipitation can be suppressed over time according to the present invention. The content of luliconazole etc. can be appropriately determined within the above range depending on the solubility in the solvent used.

[0020] Formula HOCH2 (CH2OCH2) nCompounds represented by the formula CHOH (where n is an integer) are known as polyethylene glycols (also known as macrogols or PEGs) and are readily available. For example, they can be prepared by addition polymerization of ethylene oxide and water. Compounds with an average molecular weight of 190 to 25,000 are also widely used as pharmaceutical additives. Among these, polyethylene glycol 200 with an average molecular weight of 190 to 210, polyethylene glycol 300 with an average molecular weight of 285 to 315, polyethylene glycol 400 with an average molecular weight of 380 to 420, and polyethylene glycol 600 with an average molecular weight of 570 to 630 exist as liquids at standard temperatures and are suitable for producing liquid formulations. Compounds with an average molecular weight greater than 630 exist as solids at standard temperatures, and their incorporation into liquid formulations is undesirable due to concerns about turbidity or precipitation. The pharmaceutical composition of the present invention contains polyethylene glycol with an average molecular weight of 380 to 420, which is the most effective for dissolving luliconazole and other compounds. The content of polyethylene glycol having an average molecular weight of 380 to 420 is preferably 5 to 40% by mass, more preferably 6 to 30% by mass, and even more preferably 8 to 20% by mass, relative to the total mass of the pharmaceutical composition. The average molecular weight in the present invention means a number average molecular weight, and can be calculated based on the hydroxyl value measured in accordance with JIS K 1557-1.

[0021] The pharmaceutical composition of the present invention contains ethanol as a solvent. In addition to ethanol, the pharmaceutical composition may optionally contain conventionally known solvents such as ethyl acetate, butyl acetate, isopropanol, diisopropyl sebacate, diethylene glycol dibutyl ether, xylene, dimethylacetamide, etc. The amount of ethanol is, for example, 20 to 70% by mass, preferably 30 to 68% by mass, and more preferably 40 to 65% by mass, relative to the total mass of the pharmaceutical composition. Alternatively, the amount of ethanol may be less than 50% by mass, for example, 30% by mass or more but less than 50% by mass, relative to the total mass of the pharmaceutical composition. When a component other than the solvent (e.g., a film-forming agent) contains ethanol, the amount of ethanol refers to the total amount of ethanol contained in the solvent and the components other than the solvent.

[0022] Solubilizing agents form complexes with luliconazole and other ingredients to increase solubility, and many types of solubilizing agents are available, including benzyl alcohol, acetone, glycerin, lactic acid, crotamiton, propylene carbonate, urea, and propylene glycol. The pharmaceutical composition of the present invention contains benzyl alcohol, lactic acid, propylene carbonate, and acetone. The inclusion of the specific combination of solubilizing agents increases the solubility of luliconazole and other ingredients and the stability of the pharmaceutical composition, and also improves the absorbability of the active ingredient (penetration into the nail). In the pharmaceutical composition of the present invention, the amount of solubilizing agent is desirably determined based on the solubility of luliconazole and its formulation properties (e.g., volatility and penetration into the nail). For example, the pharmaceutical composition may contain 0.01 to 10 mass%, 0.5 to 8 mass%, or 1 to 6 mass% benzyl alcohol, 1 to 10 mass%, 2 to 8 mass%, or 3 to 6 mass% lactic acid, 1 to 15 mass%, 2 to 10 mass%, or 3 to 7.5 mass% propylene carbonate, or 1 to 25 mass%, 2 to 15 mass%, or 3 to 10 mass% acetone, relative to the total mass of the pharmaceutical composition. In addition to benzyl alcohol, lactic acid, propylene carbonate, and acetone, the pharmaceutical composition of the present invention may also contain known solubilizing agents (e.g., glycerin, crotamiton, urea, propylene glycol, etc.).

[0023] For example, the pharmaceutical composition of the present invention may contain 5 to 12% by weight of luliconazole or a pharmaceutically acceptable salt thereof and 5 to 40% by weight of a compound of the formula HOCH2(CH2OCH2) n The composition contains polyethylene glycol having an average molecular weight of 380 to 420 and represented by CHOH (where n is an integer), 20 to 70% by mass of ethanol, 0.01 to 10% by mass of benzyl alcohol, 1 to 10% by mass of lactic acid, 1 to 15% by mass of propylene carbonate, and 1 to 25% by mass of acetone.

[0024] The pharmaceutical composition of the present invention may optionally contain a film-forming agent. The film-forming agent has the ability to form a film after the pharmaceutical composition is applied to the affected area and dried, and contains a solvent and additives. Examples of additives include copolyvidone, povidone, hydroxypropyl cellulose, hypromellose, polyvinyl alcohol polymer, acrylic resin alkanolamine, polyvinyl acetal diethylaminoacetate, and (alkyl acrylate / diacetone acrylamide) copolymer AMP. Examples of solvents include lower alcohols such as methanol, ethanol, and isopropanol, ethyl acetate, and butyl acetate. The film-forming agent is preferably a mixture of acrylic resin alkanolamine and ethanol (acrylic resin alkanolamine liquid), or a mixture of (alkyl acrylate / diacetone acrylamide) copolymer AMP (a salt of a copolymer of alkyl acrylate and diacetone acrylamide with 2-amino-2-methyl-1 propanol) and ethanol. In the pharmaceutical composition of the present invention, the total amount of the film-forming agent is, for example, 0.01 to 10% by mass, preferably 0.01 to 6% by mass, and more preferably 0.01 to 4% by mass, based on the total amount of the pharmaceutical composition. When the amount of the film-forming agent is 0.01% by mass or more, a sufficient film is formed, and when it is 10% by mass or less, the concentration of the antifungal agent in the film becomes relatively high, which is preferable.

[0025] The pharmaceutical composition of the present invention may contain an absorption enhancer, such as isopropyl myristate or N-methyl-2-pyrrolidone, as an optional ingredient; however, from the viewpoint of safety, it is preferable that the composition does not contain N-methyl-2-pyrrolidone. The coexistence of an absorption enhancer with an active ingredient can improve the absorbability of the active ingredient. The amount of absorption enhancer in the pharmaceutical composition of the present invention is desirably determined taking into consideration a sufficient absorption-enhancing effect and skin irritation. For example, the amount of absorption enhancer may be 1 to 10% by mass relative to the mass of the pharmaceutical composition.

[0026] In addition to the above-mentioned components, the pharmaceutical composition of the present invention may contain any optional components typically used in pharmaceutical compositions, provided that the effects of the present invention are not impaired. Examples of such optional components include components typically used in topical preparations, such as diisopropyl adipate, 1,3-butylene glycol, and medium-chain fatty acid triglycerides.

[0027] The pharmaceutical composition of the present invention is preferably an external medicine. The dosage form of the pharmaceutical composition is not particularly limited as long as it is one that has been conventionally used as an external pharmaceutical composition, and it can be formulated, for example, as a lotion, cream, gel, etc.

[0028] The pharmaceutical composition of the present invention can be prepared by a known method for preparing topical medicines, for example, by mixing the ingredients. There are no particular limitations on the mixing means or order. For example, luliconazole or the like can be mixed with a compound represented by the formula HOCH2(CH2OCH2) n The pharmaceutical composition of the present invention can be prepared by mixing polyethylene glycol having an average molecular weight of 380 to 420, represented by the formula CHOH (where n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone, and any additional ingredients.

[0029] The pharmaceutical composition of the present invention can be used for the treatment or prevention of onychomycosis such as tinea and candidal onychomycosis. Onychomycosis includes distal subungual onychomycosis such as distal marginal subungual onychomycosis, superficial white onychomycosis, and proximal subungual onychomycosis, and the pharmaceutical composition of the present invention is particularly useful for the treatment or prevention of distal marginal subungual onychomycosis. Examples of fungi that cause onychomycosis include Trichophyton rubrum and Trichophyton mentagrophytes. Onychomycosis may be an infection of the toenails or the fingernails.

[0030] The method of administration and dosage of the pharmaceutical composition of the present invention can be adjusted appropriately according to the symptoms, but it is recommended to administer an appropriate amount, for example, 10 to 12 mg / cm once a day. 2 It is preferable to apply it to the affected area every day until the affected nail grows back.

[0031] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0032] <Solubility test in polyethylene glycol> Formula HOCH2(CH2OCH2) n To investigate how luliconazole dissolves in polyethylene glycol 200, which is represented by CHOH (wherein n is an integer) and has an average molecular weight of 190 to 210, polyethylene glycol 300, which has an average molecular weight of 285 to 315, polyethylene glycol 400, which has an average molecular weight of 380 to 420, and polyethylene glycol 600, which has an average molecular weight of 570 to 630, the above polyethylene glycols (manufactured by NOF Corporation) were mixed with luliconazole according to the formulations shown in Table 1 below, and the properties of the solutions (presence or absence of insoluble matter (luliconazole)) were evaluated visually. The results are shown in Table 1 (values ​​in the table are in g).

[0033]

[0034] As shown in Table 1, polyethylene glycols 200, 300, 400, and 600 have high dissolving ability for luliconazole. Furthermore, it can be seen that polyethylene glycol 400 has the highest dissolving ability for luliconazole compared to polyethylene glycol 200, polyethylene glycol 300, and polyethylene glycol 600.

[0035] <Solubility and Storage Stability of Luliconazole> Luliconazole was dissolved in water in a solution of the formula HOCH(CHOCH) according to the formulation shown in Table 2 below. nPharmaceutical compositions containing one to three of benzyl alcohol, lactic acid, propylene carbonate, and acetone (Formulations 1 to 14) and pharmaceutical compositions of the present invention containing all four of these (Formulations 15 to 22) were prepared using polyethylene glycol 400 having an average molecular weight of 380 to 420, represented by CHOH (where n is an integer). Specifically, the ingredients other than luliconazole were stirred at room temperature, and luliconazole was added and dissolved to obtain lotions. The values ​​in the table represent mass %. The solution properties (presence or absence of insoluble matter (luliconazole)) and the presence or absence of luliconazole crystal precipitation after air-drying were evaluated immediately after preparation and after storage for specified periods at 25°C, 5°C, and 60°C. The solution properties were confirmed with the naked eye, and the presence or absence of crystal precipitation after air-drying was confirmed by dropping the lotion onto a glass slide, allowing it to dry naturally, and examining it under a microscope. For Preparations 1 to 14, insoluble matter was observed immediately after production or crystal precipitation was confirmed after air drying, so storage stability was not confirmed. The results are shown in Table 3.

[0036]

[0037]

[0038] Similarly, according to Table 4, comparative preparations 1 to 6 containing no polyethylene glycol and nComparative Formulations 7 to 27 were also prepared using polyethylene glycol 200, which is represented by CHOH (wherein n is an integer) and has an average molecular weight of 190 to 210; polyethylene glycol 300, which has an average molecular weight of 285 to 315; polyethylene glycol 600, which has an average molecular weight of 570 to 630; polyethylene glycol 1000, which has an average molecular weight of 950 to 1050; polyethylene glycol 1500, which is an equal mixture of polyethylene glycol 300 and polyethylene glycol 1540; polyethylene glycol 1540, which has an average molecular weight of 1300 to 1600; polyethylene glycol 4000, which has an average molecular weight of 2600 to 3800; polyethylene glycol 6000, which has an average molecular weight of 7300 to 9300; or polyethylene glycol 20000, which has an average molecular weight of 15000 to 25000. The properties of the solutions (presence or absence of insoluble matter (luliconazole)) and presence or absence of luliconazole crystal precipitation after air-drying were confirmed with the naked eye and under a microscope immediately after production and after storage for predetermined periods at 25°C, 5°C, and 60°C, as with Formulations 1 to 22. Note that insoluble matter was observed in Comparative Formulations 1 to 4 immediately after production, so storage stability was not confirmed. The results are shown in Table 5.

[0039]

[0040]

[0041] As shown in Table 3, in Formulations 15 to 22, in which all four of benzyl alcohol, lactic acid, propylene carbonate, and acetone were added to polyethylene glycol 400, no insoluble matter was observed immediately after production, and no crystals were precipitated after air-drying. Furthermore, even when stored for a predetermined period at 25°C, 5°C, and 60°C, high solubility was observed, and no insoluble matter or crystals were precipitated after air-drying. On the other hand, in Comparative Formulations 5 to 27, insoluble matter and / or crystals were precipitated after air-drying were observed under any of the storage conditions. In particular, even when all four solubilizing agents, benzyl alcohol, lactic acid, propylene carbonate, and acetone, were contained, the compound of the formula HOCH2(CHOCH2) nIn Comparative Preparations 7 to 27, which used polyethylene glycol represented by CHOH (where n is an integer) that did not have an average molecular weight of 380 to 420, precipitation of crystals was observed when air-dried after storage. This demonstrates that the pharmaceutical composition of the present invention can be stored stably over time.

[0042] According to the present invention, it is possible to provide a pharmaceutical composition for external use that can dissolve luliconazole at a high concentration and can be stored stably over time.

Claims

1. A pharmaceutical composition comprising luliconazole or a pharma- ceutical acceptable salt thereof as an active ingredient, the pharmaceutical composition comprising 5 to 12% by mass of luliconazole or a pharma- ceutical acceptable salt thereof relative to the total mass of the pharmaceutical composition, and a compound represented by the formula HOCH 2 (CH 2 OCH 2 ) n CH 2 A pharmaceutical composition comprising polyethylene glycol having an average molecular weight of 380 to 420 and represented by OH (wherein n is an integer), ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone.

2. The pharmaceutical composition according to claim 1, comprising 7 to 10% by weight of luliconazole or a pharma- ceutically acceptable salt thereof based on the total weight of the pharmaceutical composition.

3. 5 to 40% by weight of a compound of the formula HOCH, based on the total weight of the pharmaceutical composition 2 (CH 2 OCH 2 ) n CH 2 3. The pharmaceutical composition according to claim 1, comprising polyethylene glycol having an average molecular weight of 380 to 420, represented by OH (wherein n is an integer).

4. The pharmaceutical composition according to any one of claims 1 to 3, comprising 20 to 70% by weight of ethanol based on the total weight of the pharmaceutical composition.

5. The pharmaceutical composition according to claim 4, comprising 30% by mass or more and less than 50% by mass of ethanol based on the total mass of the pharmaceutical composition.

6. The pharmaceutical composition according to any one of claims 1 to 5, comprising 0.01 to 10% by weight of benzyl alcohol based on the total weight of the pharmaceutical composition.

7. The pharmaceutical composition according to any one of claims 1 to 6, comprising 1 to 10% by weight of lactic acid based on the total weight of the pharmaceutical composition.

8. The pharmaceutical composition according to any one of claims 1 to 7, comprising 1 to 15% by weight of propylene carbonate based on the total weight of the pharmaceutical composition.

9. The pharmaceutical composition according to any one of claims 1 to 8, comprising 1 to 25% by weight of acetone based on the total weight of the pharmaceutical composition.

10. The pharmaceutical composition according to any one of claims 1 to 9, further comprising isopropyl myristate.

11. The pharmaceutical composition according to claim 10, comprising 1 to 10% by weight of isopropyl myristate based on the total weight of the pharmaceutical composition.

12. The pharmaceutical composition according to any one of claims 1 to 11, further comprising a film-forming agent.

13. The pharmaceutical composition of claim 12, wherein the film-forming agent comprises a mixture of acrylic alkanolamine and ethanol or a mixture of alkyl acrylate / diacetone acrylamide copolymer AMP and ethanol.

14. The pharmaceutical composition according to claim 12 or 13, comprising 0.01 to 4% by weight of a film-forming agent based on the total weight of the pharmaceutical composition.

15. The pharmaceutical composition of any one of claims 1 to 14, further comprising N-methyl-2-pyrrolidone.

16. The pharmaceutical composition according to any one of claims 1 to 14, which does not contain N-methyl-2-pyrrolidone.

17. A pharmaceutical composition according to any one of claims 1 to 16 for the treatment or prevention of onychomycosis.

18. The pharmaceutical composition according to claim 17, wherein the onychomycosis is distal subungual onychomycosis.

19. The pharmaceutical composition of claim 17 or 18, wherein the onychomycosis is an infection of the toenails.

20. The pharmaceutical composition of claim 17 or 18, wherein the onychomycosis is an infection of the fingernails.

21. The pharmaceutical composition according to any one of claims 1 to 20, which is an external medicine.

22. The pharmaceutical composition of claim 21, to be applied to the affected area once daily.

23. A method for preparing the pharmaceutical composition according to any one of claims 1 to 22, comprising: 2 (CH 2 OCH 2 ) n CH 2 OH (where n is an integer) having an average molecular weight of 380 to 420, ethanol, benzyl alcohol, lactic acid, propylene carbonate, and acetone.